医学
浆膜炎
巨噬细胞活化综合征
肝脾肿大
关节炎
阿纳基纳
卡那努马布
皮疹
少年
免疫学
青少年类风湿关节炎
青少年慢性关节炎
托珠单抗
疾病
并发症
皮肤病科
重症监护医学
少关节炎
儿科
内科学
生物
遗传学
作者
Jennifer J. Lee,Rayfel Schneider
标识
DOI:10.1016/j.pcl.2018.04.005
摘要
Systemic juvenile idiopathic arthritis (sJIA) is a distinctive subtype of juvenile idiopathic arthritis, characterized by fever and arthritis, often accompanied by rash, sometimes by generalized lymphadenopathy, hepatosplenomegaly, and serositis. The diagnosis requires adequate exclusion of infectious, oncologic, autoimmune, and autoinflammatory diseases. Macrophage activation syndrome, a serious and potentially fatal complication of sJIA, requires prompt evaluation and treatment. Newer biologic agents, particularly interleukin-1 and interleukin-6 inhibitors, are highly effective and have transformed the treatment approach by reducing the use of systemic glucocorticoids. Primary care providers have a crucial role in monitoring children with sJIA for disease-related complications and medication-related adverse events.
科研通智能强力驱动
Strongly Powered by AbleSci AI